Clinical Trial Update: A Randomized, Double-Blind, Placebo-Controlled, Single-Dose Escalation Phase I Clinical Study to Assess the Safety, Pharmacokinetics, and Immunogenicity of HLX6018 in Healthy Subjects [Phase 1]

View source ↗

Summary

This document reports the completion of a Phase 1, randomized, double-blind, placebo-controlled, single-dose escalation study to assess the safety, pharmacokine…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Idiopathic Pulmonary Fibrosis

Drugs mentioned

• HLX6018

Snippet

Sponsor: Shanghai Henlius Biotech | Conditions: IPF | Phase 1 | Status: COMPLETED